Antiviral treatments for lamivudine‐resistant chronic hepatitis B adult patients
Referencias
Additional references
Aggarwal R, Bhatia SJ, Ranjan P, Sachdev S. Adefovir dipivoxil for chronic hepatitis B. Cochrane Database of Systematic Reviews 2006, Issue 1. [DOI: 10.1002/14651858.CD005639]
Andreone P, Gramenzi A, Cursaro C, Biselli M, Camma C, Trevisani F, et al. High risk of hepatocellular carcinoma in anti‐HBe positive liver cirrhosis patients developing lamivudine resistance. Journal of Viral Hepatitis 2004;11(5):439‐42. [PUBMED: 15357649]
Bock CT, Tillmann HL, Torresi J, Klempnauer J, Locarnini S, Manns MP, et al. Selection of hepatitis B virus polymerase mutants with enhanced replication by lamivudine treatment after liver transplantation. Gastroenterology 2002;122(2):264‐73. [PUBMED: 11832441]
Brown JL, Carman WF, Thomas HC. The clinical significance of molecular variation within the hepatitis B virus genome. Hepatology 1992;15(1):144‐8. [ISSN/ISBN 0270‐9139; PUBMED: 1727790]
Chayama K, Suzuki Y, Kobayashi M, Kobayashi M, Tsubota A, Hashimoto M, et al. Emergence and takeover of YMDD motif mutant hepatitis B virus during long‐term lamivudine therapy and re‐takeover by wild type after cessation of therapy. Hepatology 1998;27(6):1711‐6. [PUBMED: 9620347]
DeMets DL. Methods of combining randomized clinical trials: strengths and limitations. Statistics in Medicine 1987;6(3):341–50. [MEDLINE: 3616287]]
DerSimonian R, Lair N. Meta‐analysis in clinical trials. Controlled Clinical Trials 1986;7(3):177–88. [MEDLINE: 3802833]
Dienstag JL, Goldin RD, Heathcote EJ, Hann HW, Woessner M, Stephenson SL, et al. Histological outcome during long‐term lamivudine therapy. Gastroenterology 2003;124(1):105‐17. [PUBMED: 12512035]
Egger M, Smith GD, Schneider M, Minder C. Bias in meta‐analysis detected by a simple, graphical test. BMJ (Clinical Research Ed.) 1997;315:629‐34. [ISSN 0959‐8146]
Ghany M, Liang TJ. Drug targets and molecular mechanisms of drug resistance in chronic hepatitis B. Gastroenterology 2007;132(4):1574‐85. [PUBMED: 17408658]
Gluud C, Nikolova D, Klingenberg SL, Whitfield K, Alexakis N, Als‐Nielsen B, et al. Cochrane Hepato‐Biliary Group. About The Cochrane Collaboration (Cochrane Review Groups (CRGs)). 2009, Issue 2. Art. No.: LIVER.
Gunther S, von Breunig F, Santantonio T, Jung MC, Gaeta GB, Fischer L, et al. Absence of mutations in the YMDD motif/B region of the hepatitis B virus polymerase in famciclovir therapy failure. Journal of Hepatology 1999;30(5):749‐54. [PUBMED: 10365797]
Haria M, Benfield P. Interferon‐alpha‐2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995;50(5):573‐96. [PUBMED: 8586031]
Higgins JP, Thompson SG. Quantifying heterogeneity in a meta‐analysis. Statistics in Medicine 2002;21(11):1539‐58. [MEDLINE: 12111919]
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta‐analyses. BMJ (Clinical Research Ed.) 2003;327(7414):557‐60. [MEDLINE: 12958120]
Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.0.0 [updated February 2008]. The Cochrane Colloboration, 2008. Available from www.cochrane‐handbook.org.
Hunt CM, McGill JM, Allen MI, Condreay LD. Clinical relevance of hepatitis B viral mutations. Hepatology 2000;31(5):1037‐44. [PUBMED: 10796877]
Hussain M, Lok AS. Mutations in the hepatitis B virus polymerase gene associated with antiviral treatment for hepatitis B. Journal of Viral Hepatitis 1999;6(3):183‐94. [PUBMED: 10607230]
The International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidelines for Good Clinical Practice; E6(R1); Current Step 4 version. http://www.ich.org/LOB/media/MEDIA482.pdf 1996 (accessed 3 April 2009).
Kapke GE, Watson G, Sheffler S, Hunt D, Frederick C. Comparison of the Chiron Quantiplex branched DNA (bDNA) assay and the Abbott Genostics solution hybridization assay for quantification of hepatitis B viral DNA. Journal of Viral Hepatitis 1997;4(3):67‐75. [PUBMED: 9031068]
Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, et al. Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clinical Infectious Diseases 2003;36(6):687‐96. [PUBMED: 12627352]
Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. Journal of Viral Hepatitis 2004;11(2):97‐107. [PUBMED: 14996343]
Leemans WF, Ter Borg MJ, De Man RA. Review article: success and failure of nucleoside and nucleotide analogues in chronic hepatitis B. Alimentary Pharmacology & Therapeutics 2007;26(Suppl 2):171‐82. [PUBMED: 18081660]
Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 1999;30(2):567‐72. [PUBMED: 10421670]
Liaw YF. Impact of YMDD mutations during lamivudine therapy in patients with chronic hepatitis B. Antiviral Chemistry and Chemotherapy 2001;12(Suppl 1):67‐71. [PUBMED: 11594691]
Liaw YF. Natural history of chronic hepatitis B virus infection and long‐term outcome under treatment. Liver International 2009;29(Suppl 1):100‐7. [DOI: 10.1111/j.1478‐3231.2008.01941.x; PUBMED: 1478‐3223]
Lok ASF, Zoulim F, Locarnini S, Magnia A, Niro G, Decraemer H, et al. Monitoring drug resistance in chronic hepatitis B virus (HBV)‐infected patients during lamivudine therapy: evaluation of performance of INNO‐LiPA HBV DR assay. Journal of Clinical Microbiology 2002;40(10):3729‐34. [PUBMED: 130856]
Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, Schiff ER, et al. Long‐term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003;125(6):1714‐22. [PUBMED: 14724824]
Mumtaz K, Hamid S, Brok J, Jafri W. Pegylated interferon for chronic hepatitis B. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006303]
Mutaz K, Subhan A, Hamid S, Jafri W. Lamivudine for chronic hepatitis B in adults. Cochrane Database of Systematic Reviews 2007, Issue 2. [DOI: 10.1002/14651858.CD006547]
Pichoud C, Seigneres B, Wang Z, Trepo C, Zoulim F. Transient selection of a hepatitis B virus polymerase gene mutant associated with a decreased replication capacity and famciclovir resistance. Hepatology 1999;29(1):230‐7. [PUBMED: 9862871]
The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.0. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2008.
Royle P, Milne R. Literature searching for randomized controlled trials used in Cochrane reviews: rapid versus exhaustive searches. International Journal of Technology Assessment in Health Care 2003;19(4):591‐603.
Rücker G, Schwarzer G, Carpenter J. Arcsine test for publication bias in meta‐analyses with binary outcomes. Statustics in Medicine 2008;27:746‐63. [MEDLINE: 17592831; ISSN 0277‐6715]
Saldanha J, Gerlich W, Lelie N, Dawson P, Heermann K, Heath A, et al. An international collaborative study to establish a World Health Organization international standard for hepatitis B virus DNA nucleic acid amplification techniques. Vox Sanguinis 2001;80(1):63‐71. [PUBMED: 11339072]
World Health Organization. Hepatitis B ‐ Fact Sheet No 204. http://www.who.int/mediacentre/factsheets/fs204/en/index.html (accessed 29 September 2008).
Woo GW, Krahn M, Prichett S. Entecavir for chronic hepatitis B. Cochrane Database of Systematic Reviews 2007, Issue 1. [DOI: 10.1002/14651858.CD006572]
Wood L, Egger M, Gluud LL, Schulz KF, Jüni P, Altman DG, et al. Empirical evidence of bias in treatment effect estimates in controlled trials with different interventions and outcomes: meta‐epidemiological study. BMJ (Clinical Research Ed.) 2008;336(7644):601‐5.
